Literature DB >> 14654549

Immunohistochemical and mutational analyses of beta-catenin, Ki-ras, and p53 in two subtypes of colorectal mucinous carcinoma.

Satoshi Ikeda1, Yosuke Shimizu, Masahiko Fujimori, Yasuyo Ishizaki, Takeshi Kurihara, Yasutomo Ojima, Masazumi Okajima, Toshimasa Asahara.   

Abstract

PURPOSE: The adenoma-carcinoma sequence theory is accepted in carcinogenesis of colorectal carcinoma. To elucidate the nature and genetic alterations in colorectal mucinous carcinoma (MC), we analyzed clinical and pathological characteristics of colorectal MC and nonmucinous carcinoma (NMC), and, furthermore, we compared the prognoses and the statuses of the Wnt signaling pathway, Ki-ras, and p53 in these two subtypes. EXPERIMENTAL
DESIGN: Samples of colorectal MC obtained by surgical resections from 41 patients during the period from 1980 to 1999 were classified into fixed (FIX) type and floating (FLO) type (22 and 19 cases, respectively). The statuses of the Wnt signaling pathway and p53 protein were estimated by immunohistochemistry of beta-catenin and p53 proteins, respectively. The mutations in the Ki-ras gene were examined by direct sequencing.
RESULTS: The prognosis of colorectal MC was poorer than that of NMC at both stage II and stage III (P = 0.0037 and <0.0001, respectively). The survival rate of patients with the FLO type of MC was lower than that of patients with the FIX type (P = 0.021). Although the results of immunohistochemistry of beta-catenin and mutational analysis of the Ki-ras gene in the two subtypes were not significantly different; the rate of positive nuclear staining of p53 was lower in the FLO type than in the FIX type (P = 0.04).
CONCLUSIONS: Colorectal MC, particularly the FLO type, has a more aggressive nature than does colorectal NMC. The FLO type of colorectal MC may develop through different mechanisms from those through which NMC and the FIX type develop.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14654549

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  6 in total

1.  Implication of K-ras and p53 in colorectal cancer carcinogenesis in Tunisian population cohort.

Authors:  Chaar Ines; Ounissi Donia; Boughriba Rahma; Azza Ben Ammar; Amara Sameh; Taher Khalfallah; Ben Hmida Abdelmajid; Mzabi Sabeh; Bouraoui Saadia
Journal:  Tumour Biol       Date:  2014-04-25

2.  Critical analysis of mucin and signet ring cell as prognostic factors in an Asian population of 2,764 sporadic colorectal cancers.

Authors:  Min-Hoe Chew; Shen-Ann Eugene Yeo; Zhi-Peng Ng; Kiat-Hon Lim; Poh-Koon Koh; Kheng-Hong Ng; Kong-Weng Eu
Journal:  Int J Colorectal Dis       Date:  2010-08-05       Impact factor: 2.571

3.  The Prognostic Implications of FIX and FLO Patterns in Mucinous Colon Carcinomas.

Authors:  Sulen Sarioglu; Guray Akturk; Selman Sokmen; Hulya Ellidokuz; Aras Emre Canda; Mehtat Unlu; Abdullah Haluk Sirin; Ozgul Sagol; Cem Terzi; Mehmet Fuzun
Journal:  J Gastrointest Cancer       Date:  2019-06

4.  Clinicopathological features, postoperative survival and prognostic variables for cancer-related survival in patients with mucinous colorectal carcinoma.

Authors:  Sei-Ichiro Jimi; Masayuki Hotokezaka; Takuto Ikeda; Shuichiro Uchiyama; Hideki Hidaka; Naoki Maehara; Hidenobu Ishizaki; Kazuo Chijiiwa
Journal:  Surg Today       Date:  2014-06-06       Impact factor: 2.549

Review 5.  CDX-2, MUC-2 and B-catenin as intestinal markers in pure mucinous carcinoma of the breast.

Authors:  Laura García-Labastida; Raquel Garza-Guajardo; Oralia Barboza-Quintana; Irám Pablo Rodríguez-Sanchez; Jesús Ancer-Rodríguez; Juan Pablo Flores-Gutierrez; Gabriela Sofía Gómez-Macías
Journal:  Biol Res       Date:  2014-09-18       Impact factor: 5.612

Review 6.  Novel Therapeutic Strategies for Refractory Ovarian Cancers: Clear Cell and Mucinous Carcinomas.

Authors:  Tadahiro Shoji; Shunsuke Tatsuki; Marina Abe; Hidetoshi Tomabechi; Eriko Takatori; Yoshitaka Kaido; Takayuki Nagasawa; Masahiro Kagabu; Tsukasa Baba; Hiroaki Itamochi
Journal:  Cancers (Basel)       Date:  2021-12-04       Impact factor: 6.639

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.